Liposomal Encapsulated Rhodomyrtone: A Novel Antiacne Drug

Table 4

Comparison of minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of liposomal encapsulated rhodomyrtone formulation at different time against Propionibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis.

Isolates	MICs/MBCs (μg/mL)
	Rhodomyrtone	Liposomal formulation
		Before	After 6 months
			4°C	25°C
Propionibacterium acnes
NPRC 021	0.25/0.5	1/32	ND	ND
NPRC 036	0.25/1	2/32	ND	ND
NPRC 039	0.25/1	1/8	ND	ND
DMST 14916	0.25/1	1/16	ND	ND
Staphylococcus aureus
NPRC 302	1/2	1/32	1/32	1/64
NPRC 308	0.5/1	1/8	1/8	1/32
NPRC 317	0.25/1	2/32	2/64	32/128
NPRC 322	1/2	1/16	1/32	1/64
ATCC 25923	0.25/1	1/4	1/4	1/8
Staphylococcus epidermidis
NPRC 529	0.5/1	2/64	4/64	128/128
NPRC 537	0.5/2	2/32	2/32	64/64
NPRC 573	0.25/2	4/32	4/32	32/64
NPRC 577	0.25/1	2/32	2/32	4/64
ATCC 35984	0.25/2	2/8	2/8	4/32

ND: not done.